Alvotech and Cipla Gulf partnership announced

Home/Pharma News | Posted 30/08/2019 post-comment0 Post your comment

On 29 July 2019, pharmaceutical companies Alvotech and Cipla Gulf announced that they have entered into an exclusive partnership for the commercialization of an adalimumab biosimilar (AVT02), in a selection of emerging markets.

Shaking hands V13D29

AVT02 is a biosimilar to AbbVie’s Humira. In 2018, this originator biological drug was the largest selling medicine worldwide with sales of US$20 billion. Humira is indicated for the treatment of several autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease. In the treatment of these conditions, it neutralizes the tumour necrosis alpha (TNF-α).

The duo announced that, under the partnership, Alvotech will be developing and supplying the product, while Cipla Gulf will be responsible for registration and commercialization. Currently, AVT02 is in phase III clinical development and will be filing with the European Medicines Agency and US Food and Drug Administration by early 2020.

The partnership will enable Alvotech to take advantage of Cipla’s strong commercial network and market experience in many emerging markets. This will give patients improved access to biosimilars in many countries across the globe. In return, Cipla expands its portfolio of biosimilars to include a biosimilar of the highest selling biological in the world.

Related articles
Fuji Pharma acquires stake in Alvotech

Biosimilar partnerships for Alvotech and Pall Biotech

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Collaborations to commercialize oncology biosimilars
Cancer Cell V13I20
Home/Pharma News Posted 22/10/2021
Licensing agreements signed for ustekinumab biosimilars
IBD 1
Home/Pharma News Posted 17/09/2021
Oncogen–BrightGene partnership
104 MD001918
Home/Pharma News Posted 10/09/2021
Menagen–CKD Middle Eastern partnership
01 AA007239
Home/Pharma News Posted 03/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010